We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Geron Stock Up More Than 200% in 2018 So Far: Here's Why
Read MoreHide Full Article
Geron Corporation (GERN - Free Report) shares have risen 218.3% so far this year against the industry’s decline of 1.7% as it makes rapid progress on the development of its sole pipeline candidate, imetelstat.
Imetelstat is being evaluated as a treatment for hematologic myeloid malignancies like myelofibrosis (“MF”) in a phase II IMbark study and myelodysplastic syndromes (“MDS”) in a phase II/III IMerge study. Notably, both the studies are being conducted by Geron’s collaboration partner Johnson & Johnson’s (JNJ - Free Report) through its subsidiary Janssen. The candidate enjoys orphan drug designation for both the indications.
Pipeline Progress
Janssen has stopped enrolling patients and is currently analyzing the IMbark study based on certain protocols to reach a decision on whether to continue the study. The decision is expected by the end of this month.
The IMerge study was expanded in November last year and additional 25 patients have been enrolled in a refined MDS indication..
Preliminary data presented in December 2017 showed that more than half of the patients in the study-arm who have not received prior treatment with either lenalidomide or a hypomethylating agent for at least 8 weeks achieved RBC transfusion-independence (RBC-TI – reduced or no requirement of RBC transfusion over a certain interval) upon treatment with imetelstat. Janssen will seek confirmation of these clinical benefit and safety observed in the preliminary analysis in the 25 additional patients.
Although, the single pipeline candidate is a concern and Acceleron Pharma Inc. and its partner Celgene Corporation’s luspatercept may give a competition to imetelstat, the rally in the stock shows investor’s confidence in Geron’s progress.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Geron Stock Up More Than 200% in 2018 So Far: Here's Why
Geron Corporation (GERN - Free Report) shares have risen 218.3% so far this year against the industry’s decline of 1.7% as it makes rapid progress on the development of its sole pipeline candidate, imetelstat.
Imetelstat is being evaluated as a treatment for hematologic myeloid malignancies like myelofibrosis (“MF”) in a phase II IMbark study and myelodysplastic syndromes (“MDS”) in a phase II/III IMerge study. Notably, both the studies are being conducted by Geron’s collaboration partner Johnson & Johnson’s (JNJ - Free Report) through its subsidiary Janssen. The candidate enjoys orphan drug designation for both the indications.
Pipeline Progress
Janssen has stopped enrolling patients and is currently analyzing the IMbark study based on certain protocols to reach a decision on whether to continue the study. The decision is expected by the end of this month.
The IMerge study was expanded in November last year and additional 25 patients have been enrolled in a refined MDS indication..
Preliminary data presented in December 2017 showed that more than half of the patients in the study-arm who have not received prior treatment with either lenalidomide or a hypomethylating agent for at least 8 weeks achieved RBC transfusion-independence (RBC-TI – reduced or no requirement of RBC transfusion over a certain interval) upon treatment with imetelstat. Janssen will seek confirmation of these clinical benefit and safety observed in the preliminary analysis in the 25 additional patients.
Although, the single pipeline candidate is a concern and Acceleron Pharma Inc. and its partner Celgene Corporation’s luspatercept may give a competition to imetelstat, the rally in the stock shows investor’s confidence in Geron’s progress.
Geron Corporation Price
Geron Corporation Price | Geron Corporation Quote
Zacks Rank
Geron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>